MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an impressive 112% stock return over the past year, has announced promising results from a feasibility study of its Nanosecond PFA 360° Cardiac Catheter System in treating atrial fibrillation (AF), a common heart rhythm disorder. According to InvestingPro analysis, the company currently trades above its Fair Value, reflecting strong investor confidence in its innovative medical technologies. The initial cohort of 30 patients treated with the system demonstrated a 92.4% success rate in pulmonary vein isolation (PVI) at approximately three months post-procedure.
During the study, all lesions achieved acute success with conduction block, and the average total PVI ablation time was 11.6 minutes. The average total procedure and fluoroscopy times were 88.3 minutes and 6.9 minutes, respectively, with a left atrial dwell time of 29.6 minutes. The study reported one primary serious adverse event (cardiac perforation) and two other adverse events, including vertigo and creatinine elevation, all of which were resolved without sequelae.
The data, presented at the 30th Annual AF Symposium 2025, highlight the potential of the Nanosecond PFA 360° Cardiac Catheter to offer a more efficient workflow for clinicians. The study's lead investigator, Dr. Vivek Reddy, emphasized the system's ability to deliver consistent, durable transmural ablations due to its pliable catheter design and differentiated energy. InvestingPro data shows the company maintains a strong financial position with a current ratio of 11.93, indicating robust liquidity to support its ongoing research and development efforts.
Pulse Biosciences' CEO, Paul LaViolette, expressed confidence in the novel technology and its ability to improve the safety, efficacy, and efficiency of AF ablation. The company plans to begin an IDE study within the year for further clinical validation and to pursue commercial approval.
The nsPFA 360° Cardiac Catheter was also showcased in a live case transmission at the symposium, demonstrating its integration with 3D mapping and navigation systems.
This report is based on a press release statement from Pulse Biosciences, a bioelectric medicine company focusing on developing its CellFX nsPFA technology for various medical applications, including AF treatment. Pulse Biosciences, headquartered in Miami, Florida, aims to improve patient quality of life through health innovation. InvestingPro subscribers can access 10 additional ProTips and a comprehensive research report on PLSE, including detailed analysis of the company's financial health, which currently rates as GOOD according to InvestingPro's proprietary scoring system. Analysts are particularly optimistic about the company's prospects, forecasting profitability in the coming year.
In other recent news, Pulse Biosciences has seen significant developments. The company has appointed Paul A. LaViolette as Chief Executive Officer, bringing his extensive healthcare and venture investment experience to the role. Additionally, Pulse Biosciences has reported promising preliminary results from a feasibility study on its Nanosecond Pulsed Field Ablation (nano-PFA) technology, showing potential in reducing benign thyroid nodules and providing symptomatic relief.
The company has also disclosed the departure of its President and CEO, Mr. Burke T. Barrett, with interim leadership assumed by Kevin P. Danahy and Darrin R. Uecker. Furthermore, major stockholder and Co-Chairman, Robert W. Duggan, is considering substantial market purchases of the company's common stock.
In terms of financials, despite recording a GAAP net loss of $12.7 million for Q3 2024, Pulse Biosciences successfully raised $60 million through a rights offering, ending the quarter with $79 million in cash and cash equivalents. The company continues to make strides with its nano-PFA technology, treating its first Atrial Fibrillation patients in Europe using the nano-PFA Cardiac Surgical System, which has received U.S. FDA breakthrough device designation. These are some of the recent developments within Pulse Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.